Immuron Ltd — Capital/Financing Update 2008

Jun 4, 2008

==> picture [66 x 74] intentionally omitted <==

Anadis SSPP oversubscribed raising $823,000

Thursday 5 June 2008

Anadis Limited is delighted to announce the successful completion of its Shareholder Share Purchase Plan (SSPP). The SSPP came in oversubscribed raising a total of $823,000. The SSPP was originally limited to $750,000, but due to an overwhelming support on the final day of the offering, the directors decided that it would not be appropriate to prevent some shareholders from participating in this opportunity.

Anadis CEO, Dr Zeil Rosenberg, said, “The response to the Shareholder Share Purchase Plan has been overwhelming and reinforces our own belief in the opportunities for the Anadis antibody technology platform. I would like to thank the continuing support of shareholders.”

“These new funds will help accelerate our plans to successfully commercialise our important products, including development of new clinical trials, to improve human health and create shareholder value. I look forward to further announcements in the near future informing our shareholders about these important developments in their company.”

For further information contact:

Dr. Zeil Rosenberg – CEO zeil@anadis.com Tel: +1 646 402 5289

Arie Nudel - Investor Relations arie@anadis.com Tel: +61 3 9358 6388

About Anadis ( http://www.anadis.com):

Anadis Limited (ASX: ANX, OTC:ANDIY) is a biopharmaceutical company producing antibodies and other bioactive proteins as health products. Its all-natural, orally administered and colostrumderived platform is proven safe and effective, with regulatory classification as GRAS (Generally Regarded as Safe) and BSE-free certification, allowing for rapid progression from concept to market. The company’s core technology relies on advanced dairy industry processing methods including immunization of pregnant cows with proprietary antigen specific vaccines, which in turn elicit an immune response by the cow. First-milking colostrum contains more than 35% immunoglobulin and this targeted antibody, along with other immune system bioactive nutrients, is subsequently harvested, fractionated and freeze dried under the highest dairy industry standards. The company is addressing a variety of unmet human health needs with broad market demand, including: Oral and GI Mucositis; Inflammatory Bowel Disease (IBD); Irritable Bowel Syndrome (IBS); Travellers’ Diarrhea; Influenza, Clostridium Difficile and Rotavirus. The company operates from Melbourne, Australia and New York City.

==> picture [47 x 53] intentionally omitted <==